These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36507149)

  • 1. Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries.
    Pinto Cardoso G; Lagrée-Chastan M; Caseris M; Gaudelus J; Haas H; Leroy JP; Bakhache P; Pujol JF; Werner A; Dommergues MA; Pauquet E; Pinquier D
    Front Pediatr; 2022; 10():1000657. PubMed ID: 36507149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
    Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V
    Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.
    Bousema JC; Ruitenberg J
    Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review.
    Begum S; Herrera-Restrepo O; Rolland C; Purushotham S; Andani A; Shah H; Kocaata Z
    Hum Vaccin Immunother; 2024 Dec; 20(1):2406613. PubMed ID: 39373020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies.
    Booy R; Gentile A; Nissen M; Whelan J; Abitbol V
    Hum Vaccin Immunother; 2019; 15(2):470-480. PubMed ID: 30296197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents.
    Biolchi A; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Budroni S; Giuliani MM; Rappuoli R; Boucher P; Pizza M
    Infect Dis Ther; 2021 Mar; 10(1):307-316. PubMed ID: 33185849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.
    Tin Tin Htar M; Jackson S; Balmer P; Serra LC; Vyse A; Slack M; Riera-Montes M; Swerdlow DL; Findlow J
    BMC Public Health; 2020 Dec; 20(1):1890. PubMed ID: 33298015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
    Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
    Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination.
    Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB;
    Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
    Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
    Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany.
    Gruhn S; Batram M; Wick M; Langevin E; Scholz S; Greiner W; Damm O
    Infect Dis Ther; 2024 Apr; 13(4):907-920. PubMed ID: 38570446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2022 Jan; 40(4):666-672. PubMed ID: 34996641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease.
    Taha MK; Martinon-Torres F; Köllges R; Bonanni P; Safadi MAP; Booy R; Smith V; Garcia S; Bekkat-Berkani R; Abitbol V
    Expert Rev Vaccines; 2022 May; 21(5):659-674. PubMed ID: 35271781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
    Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
    Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential public health impact of a
    Huang L; Snedecor SJ; Balmer P; Srivastava A
    Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination.
    Aparecido Nunes A; De Jesus Lopes De Abreu A; Cintra O; A C T Cintra M; Barbosa Coelho E; Nogueira Castro De Barros E
    Vaccine; 2021 Jan; 39(3):605-616. PubMed ID: 33358262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.